Current thinking in the treatment of hypertension

Practitioner

Volumn 246, Issue 1635, 2002, Pages 408-414

  Lobo, Mel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; BLOOD PRESSURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 0042737831     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. [Review] [77 refs]. Arch Int Med 1993;153(5):598-615
2. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. [see comments]. N Engl J Med 1993;329(26):1912-1917
3. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. [see comments]. Lancet 1990;335(8692):765-774
4. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Int Med 1992;152(1):56-64
5. van den Hoogen PC, Feskens EJ, Nagelkerke NJ et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. [see comments]. N Engl J Med 2000;342(1):1-8
6. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001;38(4):827-832
7. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? [Review] [78 refs]. J Hum Hypertension 1997;11(4):213-220
8. Joffres MR, Ghadirian P, Fodor JG et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertension 1997;10(10 Pt 1):1097-1102
9. Mancia G, Sega R, Milesi C et al. Blood-pressure control in the hypertensive population. [see comments]. Lancet 1997;349(9050):454-457
10. Ramsay LE, Williams B, Johnston GD et al. British Hypertension Society guidelines for hypertension management 1999: summary. [see comments]. BMJ 1999;319(7210):630-635
11. Whelton PK, Appel LJ, Espeland MA et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. [see comments]. [erratum appears in JAMA 1998 Jun 24;279(24):1954]. JAMA 1998;279(11):839-846
12. Midgley JP, Matthew AG, Greenwood CM et al. Effect of reduced dietary sodium on blood pressure: a metaanalysis of randomized controlled trials. [see comments]. JAMA 1996;275(20):1590-1597
13. Kaplan NM. Alcohol and hypertension. Lancet 1995;345(8965):1588-1589
14. Applegate WB, Miller ST, Elam JT et al. Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension. Arch Int Med 1992;152(6):1162-1166
15. Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. [see comments]. New Eng J Med 1997;336(16):1117-1124
16. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. [see comments]. JAMA 1996;275(19):1507-1513
17. Ruilope LM, Campo C, Rodicio JL. Blood pressure control, proteinuria and renal outcome in chronic renal failure. [Review] [28 refs]. Curr Opin Nephrology Hypertension 1998;7(2):145-148
18. Schiffrin EL, Park JB, Intengan HD et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. [see comments]. Circulation 2000;101(14):1653-1659
19. Dahlof B et al for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
20. Freis ED, Materson BJ, Flamenbaum V. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med 1983;74(6):1029-1041
21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. [see comments]. JAMA 1991;265(24):3255-3264
22. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). [see comments]. Lancet 1991;338(8778):1281-1285
23. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. [see comments]. Lancet 1997;350(9080):757-764
24. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. [see comments]. Lancet 1999;354(9192):1751-1756
25. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. [see comments]. JAMA 1998;279(23):1903-1907
26. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. [see comments]. [erratum appears in Arch Intern Med 1998 Mar 23;158(6):573]. Arch Inter Med 1997;157(21):2413-2446
27. Arauz-Pacheco C, Parrott MA, Raskin R. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002;25(1):134-147
28. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. [see comments]. [erratum appears in BMJ 1999 Jan 2;318(7175):29]. BMJ 1998;317(7160):703-713
29. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. [see comments]. New Engl J Med 2001;345(12):861-869
30. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. [see comments]. New Engl J Med 2001;345(12):851-860
31. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. [see comments]. New Engl J Med 2001;345(12):870-878
32. Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ 1988;297(6658):1227-1230
33. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. [see comments]. Lancet 1998;351(9118):1755-1762
34. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. [see comments]. Lancet 2001;358(9287):1033-1041
35. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. [see comments]. [erratum appears in 2000 May 4;342(18):1376; N Engl J Med 2000 Mar 9;342(10):748]. New Engl J Med 2000;342(3):145-153
36. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. New Engl J Med 2001;348(18):1291-1297